<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724098</url>
  </required_header>
  <id_info>
    <org_study_id>T30/2016</org_study_id>
    <nct_id>NCT02724098</nct_id>
  </id_info>
  <brief_title>Bioavailability of Subcutaneous Dexmedetomidine</brief_title>
  <acronym>ScDex</acronym>
  <official_title>Bioavailability of Subcutaneously Given Dexmedetomidine in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Turku University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Turku University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the pharmacokinetics of subcutaneously administered&#xD;
      dexmedetomidine in healthy volunteers. The absolute bioavailability of subcutaneously&#xD;
      administered dexmedetomidine will be calculated. In addition, the investigators will report&#xD;
      the effects of subcutaneously administered dexmedetomidine on plasma catecholamine levels,&#xD;
      vital signs such as systemic blood pressure, heart rate and sedation. The investigators will&#xD;
      also monitor the local and systemic safety and tolerability of subcutaneously administered&#xD;
      dexmedetomidine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">May 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability (%) of subcutaneously given dexmedetomidine</measure>
    <time_frame>10 hours</time_frame>
    <description>Noncompartmental analysis after non-linear mixed effects modelling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameter (blood pressure)</measure>
    <time_frame>10 hours</time_frame>
    <description>More than 30% change from the baseline in the blood pressure (measured in mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameter (heart rate)</measure>
    <time_frame>10 hours</time_frame>
    <description>More than 30% change from the baseline in the blood pressure (measured in beats/minute)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>intravenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) diluted in 10 ml of sodium chloride will be administered intravenously in 10 min at a constant rate using an infusion pump.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subcutaneous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 µg/kg dexmedetomidine (dexmedetomidine hydrochloride 100 microg/ml, Dexdor® Orion Oyj, Espoo, Finland) will be administered subcutaneously undiluted.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <arm_group_label>intravenous</arm_group_label>
    <arm_group_label>subcutaneous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fluent skills in the Finnish language in order to be able to give informed consent and&#xD;
             communicate with the study personnel.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Male gender.&#xD;
&#xD;
          -  Weight ≥ 60 kg.&#xD;
&#xD;
          -  Written informed consent from the subject.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of intolerance to the study drug or related compounds and additives.&#xD;
&#xD;
          -  Concomitant drug therapy of any kind except paracetamol in the 14 days prior to the&#xD;
             study.&#xD;
&#xD;
          -  Existing or recent significant disease.&#xD;
&#xD;
          -  History of any kind of drug allergy.&#xD;
&#xD;
          -  Previous or present alcoholism, drug abuse, psychological or other emotional problems&#xD;
             that are likely to invalidate informed consent, or limit the ability of the subject to&#xD;
             comply with the protocol requirements.&#xD;
&#xD;
          -  Donation of blood within six weeks prior to and during the study.&#xD;
&#xD;
          -  Body weight &lt; 60 kg or BMI &gt; 30 kg / m2.&#xD;
&#xD;
          -  Participation in any other clinical study involving investigational or marketed drug&#xD;
             products concomitantly or within one month prior to the entry into this study.&#xD;
&#xD;
          -  Smoking during one month before the start of the study or during the study period.&#xD;
&#xD;
          -  Clinically significant abnormal findings in physical examination, ECG or laboratory&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teijo I Saari, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. Anaesthesiology and Intensive Care, University Of Turku</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Perioperative Services, Intensive Care and Pain Therapy, Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <zip>20521</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>March 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Palliative Therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>June 15, 2020</submitted>
    <returned>July 1, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

